Evolus Strategic Advantage and Growth
LOVVOLUS
MARKET EXPANSION OPPORTUNITY—FILLERS
THE ADDITION OF EVOLYSSE FILLERS EXPANDS
OUR ADDRESSABLE MARKET BY 78%¹
TM 2
EVOLYSSE™
Estyme
3
JeuveauⓇ
prabotulinumtoxinA-xvfs injection
FILLERS
NEUROTOXINS
$10.2B
$4.5B
$5.7B
769
$2.5B
$5.7B
$3.2B
2022
2028
1.
Includes U.S., Canada, Europe and Australia aesthetic neurotoxin markets. Source: Medical Insight, Inc. Cosmetic Neurotoxin Market Study, Jan. 2023, Medical Insights Dermal Filler Market Study,
March 2023 (www.miinews.com), data on file: Decision Research Group (DRG) Aesthetic Injectables Market Insights, Europe, 2021, BCG Aesthetic Research presented at IMCAS 2023 and company
estimates.
2.
Evolysse is licensed in the U.S. only and is not currently available for sale.
3.
Estyme is licensed in the UK and Europe. Not currently available for sale.View entire presentation